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blets (n529, 72%), particularly carboplatin-paclitaxel (n285, 39%), accounted for
most off-label GL concordant care. NCCN GL recommendations for carboplatin-
based doublets are supported by phase III clinical trials. CONCLUSIONS: The ma-
jority of advanced NSCLC patients received first-line therapy that was concordant
with NCCN GL recommendations but was outside the FDA labeled indication.
These GL concordant, off-label uses are supported by high-level evidence including
phase III clinical trials.
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OBJECTIVES: The aim of this study was to assess treatment choices for patients
diagnosed withmetastatic melanoma in SUS settings.METHODS: The patient flow
pathway was determined by patients receiving systemic therapy for diagnosed
melanoma stage IV (ICD-C43) from a government administrative database (SIA/
DATASUS). Patients ineligible for upfront therapy could not be captured. Systemic
therapy at each line treatment and time to progression data from Jan/2008 to Jun/
2010 was collected. Patients were classified as active (analyzed during all period),
lost during follow-up (unknown reason) and dead. RESULTS: Data from 1,049 pa-
tients was analyzed, 48.1% lost follow up and 8.3% had documented death. By the
end of the study, 43.6% were still active. The average follow-up time was 8.6
months. All patients received at least one line of systemic therapy. First line ther-
apy (FLT), 49.7% received dacarbazine and 29.1% interferon. By Jun/2010, 175
(16.7%) patients received second line therapy (SLT), 42.5% lost follow-up, 6.6% died
and 34.2% remained in FLT. The most common SLT regimens were dacarbazine
(28.0%), interferon (17.7%) and paclitaxel (14.9%) and the average time to switch
from FLT to SLT was 5.5 months. During SLT, 28.0% lost follow-up, 7.4% died and
47.4%of patient remained active till jun/2010. Thirty patients (2.9%) received a third
line therapy (TLT), with an average time from the beginning of SLT to TLT of 5.2
months. Paclitaxel (23.3%) and interferon (20.0%) were the most commonly used
regimens. CONCLUSIONS: For metastatic melanoma patients in the SUS, the main
chemotherapy regimens in FLT and SLT were dacarbazine and interferon. Pacli-
taxel was the most common TLT agent along with interferon.
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OBJECTIVES: The objective of this systematic review was to identify treatment
guidelines for metastatic colorectal cancer (mCRC) and to assess guideline
recommendations. METHODS: Publications were identified through electronic
searches of MEDLINE, MEDLINE In Process, EMBASE and the Cochrane Library;
through manual searches of the reference lists of relevant articles; and by search-
ing websites on the Internet. The MEDLINE and EMBASE searches were limited to
articles published in English, whereas the Cochrane library search had no language
restrictions.RESULTS:A total of 1,633 citations/abstractswere identified fromelec-
tronic database searches. Of these, 91 underwent full-paper review and 32 were
included in the final analysis. In addition, 25 articles were identified from manual
andwebsite searches, giving a total of 57 guidelines. The guidelineswere published
between 1996 and 2010, with the majority published between 2004 and 2010. The
country publishing the most guidelines was the USA (12), followed by the UK (10),
Canada (8), France (8), Germany (3), Australia (2), Spain (2) and Italy (1). In addition,
eight European and three International guidelines were identified. As monoclonal
antibody therapy for mCRC was not introduced until 2004, no firm recommenda-
tions formonoclonal antibody therapyweremade in guidelines published between
2004 and 2006. Recommendations for monoclonal antibody therapy first appeared
in 2007 and evolved asmore data became available. Themost recent international,
European, and US guidelines recommended combination chemotherapy with a
monoclonal antibody for the first-line treatment of mCRC, while second-line treat-
ment varied depending on the first-line regimen used. Cetuximab and panitu-
mumab were recommended in patients with wild-type KRAS mCRC.
CONCLUSIONS: The findings from this systematic review indicate that these re-
cent treatment guidelines have recognized the role ofmonoclonal antibodies in the
management of mCRC; and timely treatment guideline updates are necessary to
reflect the most recently available data.
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OBJECTIVES: This study aims to describe clinical and demographic characteristics
of chronic myelogenous leukemia (CML) patients receiving therapy on public can-
cer centers in São Paulo state, Brazil. METHODS: Cross-sectional analysis of São
Paulo state CML-related pharmacy claims as reported in the Ambulatory Informa-
tion System database. Patients were included if they have at least one claim with
CML ICD-10 code during April 2010. Repeated records were excluded using identi-
fication code, age, sex, and diagnosis date as compatibility criteria. Kruskal-Wallis
test was used to compare clinical and demographical variables and cost of treat-
ment among patients receiving each protocol. RESULTS: 1,326 patients were iden-
tified as CML patients, 53.32%male with a mean age of 51.08 years (SD17.07). The
mean disease duration was 2.38 years (SD3.02; range 0-21.27 years) for those
patients for whom data was available (n1,307). The proportion of patients receiv-
ing tyrosine kinase inhibitors (TKI)was 85.67% (imatinib74.06%; dasatinib8.82%;
nilotinib2.79%). Other reported therapeutic strategies were: hydroxyurea (7.24%),
non specified oral cancer therapy (3.17%), chemotherapy protocols (0.75%), inter-
feron (0.60%), and others (2.56%). Median age was significantly (p0.05) different
among hydroxyurea-treated patients (67 years), others (46 years), and chemother-
apy (15 years) as compared to TKI, interferon and non specified oral drugs. Higher
median disease duration was observed for nilotinib-treated patients (4.74 years),
interferon (2.73), and dasatinib (2.31). The median disease duration of imatinib
treated patients was 0.96 years (p0.05 vs. all comparisons except hydroxyurea).
Themedian cost of treatment ranged from 80 BRL to 6,678 BRL for hydroxyurea and
nilotinib (p0.05). CONCLUSIONS: Among this sample, the most frequent thera-
peutic approach for CML patients was TKI, particularly imatinib, but second-gen-
eration TKIs have also been prescribed for patients with significantly longer dis-
ease duration, which is consistent with current guidelines that recommend that
they should be prescribed in later lines.
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OBJECTIVES: The aim of this study is to document treatment patterns of care and
associated costs of metastatic melanoma in Brazil from the Public Health System
(SUS) Perspective. METHODS: A review of a government administrative claims
database (Outpatient Information System - SIA/DATASUS)was conducted from Jan
2008 to June 2010. Patients receiving radiotherapy and/or systemic therapy for
diagnosed melanoma (International Code of Disease (ICD-10) C43) stage IV were
included in the analysis. Information on type of treatment (chemotherapy, radio-
therapy), chemotherapy scheme, length of treatment and associated costs (in 2010
USD)were collected.RESULTS: 2,488 patientsmet the inclusion criteria, 54.3%male
with an average age (SD) of 56.3 (15.0) years. 42.2% lived in the Southeast region and
38.5% in the South. Less than 40% of the cases had the primary cancer site reported.
Dacarbazine was the most widely used agent (administered to 1,700 patients),
followed by interferon (1,059 patients) and cisplatin (435 patients). Dacarbazine
monotherapy was the most commonly administered chemotherapy regimen
(37.9% of the patients; average length of treatment of 3.1 months), followed by
interferon monotherapy (30.1% of the patients; average length of treatment of 4.6
months) and paclitaxel monotherapy (3.5% of the patients; average length of treat-
ment of 2.8 months). Overall cost of care expenses were USD16,238,160, 99% of the
cost was attributable to chemotherapy (USD16,024,555). Total expenses in 2009
(USD6,667,687) increased 12% compared to 2008; interferon monotherapy ac-
counted for 38.5% (USD6,245,742) of expenses, and dacarbazine monotherapy ac-
counted for 32.2% (USD5,230,315). CONCLUSIONS: Patients with advanced mela-
noma, in the Brazilian Public Healthcare System (SUS), nearly all receive systemic
therapy. Dacarbazine as single agent is the most common regimen, followed by
interferon with a significant financial impact to the Public Healthcare System, to-
talizing USD16,238,160 in the last two and a half years.
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OBJECTIVES: NSCLC (accounting for 80% of all cases of lung cancer) causes high
morbidity and mortality. Various treatment lines are available for NSCLC, and
there are ongoing discussions on the most appropriate measure of treatment effi-
cacy for reimbursement decisions. We examined the use of these endpoints in
NSCLC from a payers’ perspective.METHODS: Targeted searches were conducted
in MEDLINE® and the Cochrane Database of Reviews, using clinical and health
economic-related key words and limited from 2000 to 2010. RESULTS: OS can be
measured easily and accurately in terms of both event and time and is the endpoint
preferred by regulatory bodies including the FDA and EMA. Over the last 10 years
the benchmark OS for first-line treatment of NSCLC has risen and it is increasingly
difficult to demonstrate significant OS benefit, as the efficacy (clinical trial results)
of treatments has improved. Demonstrating improvements in OS over best sup-
portive care is less challenging than against an active comparator. Adequate pow-
ering of studies to demonstrate OS benefit is vital but requires large study popula-
tions. Demonstrating a significant PFS benefit is also challenging, requiring
frequent assessments, precise event definition and exact determination of the time
of event. Nevertheless, PFS provides a well-accepted alternative endpoint to OS as
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it is a direct measure of treatment effect on tumour burden andmeasures only the
effect of the study drug. PFS has also been accepted by regulatory bodies as a
measure of the efficacy of cancer treatments. CONCLUSIONS: OS is generally re-
garded as the preferable endpoint (from a payer’s perspective) for demonstrating
clinical efficacy in NSCLC. There are challenges, however, with demonstrating OS
benefit of new therapies for NSCLC. PFS data may be more appropriate for use in
certain situations, especially those in which subsequent lines of therapy exist.
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OBJECTIVES: The objective of the study was to propose an alternative indirect
comparison method and compare it to the standard method. METHODS: In the
absence of head-to-head trials, the standard method for estimating indirect rela-
tive effectiveness is to obtain an indirect hazard ratio (HR) estimate using the two
HRs from the comparator trials against a common 3rd one. This method, however,
is only valid if the assumption of proportional hazard (PH) holds. We proposed an
alternative indirect comparison method that does not depend on the PH assump-
tion, which consists of calculating the absolute difference between treatment arms
at each two-week period in drug B trial and applying this difference to the common
comparator in drug A trial to generate the adjusted curve for drug B. This was done
for Progression free Survival (PFS) and Overall Survival (OS) from parametric esti-
mates throughout the observed and extrapolated periods. Trial data for cetuximab
and panitumumab in 1st line treatment of wild-type KRAS metastatic colorectal
cancerwas used to examine the PH assumption and compared the twomethods for
estimating the relative treatment effect between the two agents. RESULTS: The
functional form for the PFS and OS distributions was found to be different for
panitumumab versus cetuximab (Weibull shape parameter value for: PFS1.616
versus 1.761; OS1.314 versus 1.336, respectively). Thus, the PH assumption was
violated. Panitumumab trial was set as the reference (the estimated mean PFS
0.917 years and mean OS2.469). Using the standard method and our proposed
method, the indirectly estimated PFS and OS for cetuximab were: mean PFS 0.846
vs 0.920 years; mean OS 2.393 versus 2.312 years, respectively. CONCLUSIONS:
The standard methodology for indirect comparison allows easy execution. How-
ever, if the PH assumption is violated, alternative methods, such as the one pro-
posed in this study, can be considered.
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OBJECTIVES: The objective of this study was to develop a unique linked Medicare-
Medicaid-WV Cancer Registry (WVCR) de-identified dataset to determine health
care utilization, costs and overall burden of breast, colorectal, lung, and prostate
cancers diagnosed in persons  65 years of age who live in WV and to compare
themwith national estimates.METHODS: The data linkagewas performed in three
phases, following process as originally described by Potosky (1993) and adapted by
Bradley (2007) and Koroukian (2008). In phase one, a list of individual’s65 years of
age with incident diagnosis of any cancer between January 1, 2002 and December
31, 2007 was extracted from WVCR data. The SSN, Sex, and Date of Birth of these
individuals were sent to CMS to create a crosswalk file for these individuals to
include with purchased WV Medicare data. In phase two, Medicare data were
linked with WVCR data using the crosswalk file provided by CMS. In phase three,
WVCR data were linked with Medicaid enrollment file data using personal identi-
fiers. After the linkages, all identifiers were removed to create a de-identified re-
search data set. RESULTS: In phase one, we identified 42,288 individuals’65 years
of age with incident diagnosis of any cancer from 2002 to 2007 in the WVCR data.
When linked with Medicare data in the second phase, 41,575 (98.3 %) individuals
were matched. In phase three, WVCR data were matched with Medicaid enroll-
ment data for 5790 (13.7%) individuals using SSN, First Name, and Last Name; for
5860 (13.9%) individuals using SSN, Last Name, Month of Birth, and Sex; and, for
5747 (13.6%) individuals using SSN, First Name, Month of Birth, and Sex.
CONCLUSIONS: Non-participant states in SEER-Medicare can build a powerful
linked Medicare-Medicaid-Cancer Registry dataset to identify and target cancer
disparities to improve outcomes in their elderly and dual-eligible citizens.
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OBJECTIVES: Electronic medical records (EMRs) are used increasingly for research.
Our objectives were a) to understand the utility of an EMR oncology database com-
pared with SEER cancer registry data and Medicare and commercial claims data-
bases and b) to identify areas for improvement in data collection, analysis, and
interpretation in clinical oncology, epidemiology, and comparative effectiveness
research. METHODS: Demographic, clinical, and treatment characteristics in the
four databases were compared using six tumor types: breast, lung/bronchus, head/
neck, colorectum, prostate, and NHL. Data imputation was performed using the
hot-deckmethod; patient characteristics were compared using Cohen’s effect size.
We described patient and clinic inclusion criteria, treatment definitions, and pur-
poses of each database to enable comparisons. RESULTS: Sex and 10-year age
distributions for each tumor type were similar across datasets. The EMR oncology
database had a large proportion of missing data for stage (70%) and race (40%),
which were replaced with imputed values. There were several differences in racial
composition (15%) and ambulatory chemotherapy treatment (30%), andmodest
(10%), differences in distribution of tumor type likely due to differences in geo-
graphic distribution of included patients and clinics. Overall, Cohen’s effects size
analyses indicated small to medium differences (w0.3) in patient characteristics
across databases. Patients in the EMRdatabaseweremore likely to receive biologics
and less likely to receive hormones compared to those in the reference databases,
with the largest differences (40%) observed in prostate cancer patients, who are
usually seen first or primarily by urologists. CONCLUSIONS: Several factors must
be consideredwhen using EMRs for oncology research purposeswith a target of the
US cancer population, particularly when evaluating treatment patterns. Important
factors include evaluation of stage, geography, race, andmedical facilities’ special-
ization. EMR database utility might be enhanced through imputation, addition of
specific physician notes (e.g., stage) and linkage to other data sources.
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OBJECTIVES: To create an overview that makes researchers aware of the available
database linkages in Northern America and Europe which facilitate pharmacoepi-
demiologic studies in cancer patients.METHODS: In addition to our own database,
i.e. the Eindhoven Cancer Registry (ECR) linked to the PHARMO RLS, we considered
database linkages between a population-based cancer registry, that provides de-
tailed tumor information of incident cancer cases, and an administrative health-
care database, that at least contains information on drug use and offers a longitu-
dinal perspective on health care utilization before, during and after cancer
diagnosis. Eligible database linkages should have been used in multiple published
articles in English language included in Pubmed. The Cancer Research Network
(CRN) in the United States was excluded from this review, as an overview of the
linked databases participating in the CRN is already provided elsewhere. Research-
ers who hadworkedwith the data resources included in our reviewwere contacted
for additional information and verification of the data presented in the overview.
RESULTS: Ten database linkages met the inclusion criteria: the SEER-Medicare,
cancer registry data linked to Medicaid, the British Columbia Cancer Registry and
Health data, the Saskatchewan Health Plan Databases, the Scottish cancer registry
linked to the Tayside drug dispensing data, linked databases in the Nordic Coun-
tries of Europe: Norway, Sweden, Finland and Denmark, and the ECR-PHARMO
linkage in The Netherlands. Descriptives of included database linkages comprise
population size, generalizability of the population, year of first data availability,
vital status, contents of the cancer registry, contents of the administrative health-
care database, the possibility to select a cancer-free control cohort, and linkage to
other health care databases. CONCLUSIONS: Various valuable resources of infor-
mation are available to study the disease management of cancer, including treat-
ment patterns and outcomes assessments, creating new opportunities for post-
approval evaluation of anti-cancer drugs.
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OBJECTIVES: Cancer treatment models are often based on progression-free sur-
vival (PFS) and overall survival (OS) data. If the model objective requires extrapo-
lating results or exploring “what-if” scenarios, disease progression parameters are
calibrated so that the model replicates the PFS and OS data. Uncertainties in the
estimation of the Kaplan-Meier survival curves used as calibration targets, and in
the model calibration process itself, are not commonly incorporated into sensitiv-
ity analyses. The objective of this study was to demonstrate methods for incorpo-
rating these uncertainties into probabilistic sensitivity analyses (PSA) and to ex-
plore their implications. METHODS: We constructed hypothetical PFS and OS
survival (with censoring) for two treatments (TxA & TxB) and a corresponding
three-state Markov model (Non-progressed (NP), Progressed (P), Dead (D)). Health
states were assigned costs and utilities consistent with advanced cancer. Three
transition probabilities for each treatment (NP-P, NP-D, P-D) were calibrated
(using Excel Solver) to simultaneously fit (using mean squared deviation) the
PFS/OS curves. We performed three increasingly comprehensive PSAs using sec-
ond-order Monte Carlo simulation (SMCS): 1) conventional PSA including only
probability distributions of costs and utilities; 2) specifying beta distributions for
failure probabilities at each PFS/OS timepoint, simulatingmultiple replicates of the
PFS /OS data from these distributions, re-estimating and refitting the curves for
each replicate, and incorporating the resulting calibrated parameter sets into the
SMCS; and 3) incorporating different curve-fitting methods by varying Solver pa-
rameters (initial values, constraints, objective function). Uncertainty in cost-effec-
tiveness results was represented by cost-effectiveness acceptability curves (CEAC).
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